Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11201 - 11225 of 11564 in total
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India . The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest . Once the plasmid DNA is introduced into host cells and the viral protein is translated,...
Investigational
Matched Description: … The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid ... Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a
GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma).
Investigational
Matched Description: … GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability …
Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer).
Investigational
Matched Description: … Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination …
TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental procedures.
Investigational
Matched Description: … TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such …
Idronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.
Investigational
Matched Description: … Idronoxil is a substance that is being studied in the treatment of cancer. …
Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.
Investigational
Matched Description: … Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that …
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
Matched Description: … Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes …
A selective androgen receptor modulator with minimal prostate hypertrophic activity, enhances lean body mass in male rats and stimulates sexual behavior in female rats.
Experimental
Matched Description: … A selective androgen receptor modulator with minimal prostate hypertrophic activity, enhances lean body …
An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.
Experimental
Matched Description: … It is a metal and ingestion will lead to CADMIUM POISONING. …
Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)).
Investigational
Matched Description: … Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy …
TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).
Investigational
Matched Description: … TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability …
Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
Investigational
Matched Description: … Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, …
Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 …
Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)).
Investigational
Matched Description: … Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With …
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
Investigational
Matched Description: … It is a technetium-99m radiolabeled [heparin]. …
Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits...
Investigational
Sar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.
Investigational
Matched Description: … Sar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. …
Methylmethionine chloride may be useful in helping the healing of gastric ulcers. In Japan, it is used as an over the counter product for gastrointestinal health support. It is also called "Vitamin U", but it is not a true vitamin.
Experimental
Matched Description: … It is also called "Vitamin U", but it is not a true vitamin. …
Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)).
Investigational
Matched Description: … Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the …
BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects).
Investigational
Matched Description: … BPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 …
Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).
Investigational
Matched Description: … Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of …
Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).
Investigational
Matched Description: … Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of …
MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).
Investigational
Matched Description: … MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics …
LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).
Investigational
Matched Description: … LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or …
CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Investigational
Matched Description: … CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab …
Displaying drugs 11201 - 11225 of 11564 in total